长非编码RNA HAS2-AS1 的值作为质瘤的诊断和预后标志物
1The Fourth Department of Neurosurgery, Tangshan Gongren Hospital, 063000 Tangshan, China.
Neurologia
|April 14, 2024
概括
长非编码RNA HAS2-AS1在质瘤中被上调,作为诊断标记物,表明预后不佳. 在质瘤患者中,HAS2-AS1的过度表达与总体和无进展生存时间的减少有关.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 质瘤的发病率很高,预后不好,需要新的治疗策略.
- 长非编码RNAs (lncRNAs) 在各种疾病中发挥调节作用,包括质瘤.
- HAS2-AS1,一个lncRNA,涉及到几种癌症类型的瘤发生.
研究的目的:
- 评估lncRNA HAS2-AS1作为质瘤的诊断和预后生物标志物的潜力.
- 与正常组织相比,研究质瘤组织中HAS2-AS1的表达水平.
主要方法:
- 利用癌症基因组图谱 (TCGA) 数据库进行miRNA和临床数据分析.
- 在80个质瘤患者样本和相邻的正常组织中检查了HAS2-AS1表达.
- 用于诊断和预后评估的雇佣接收器操作特征 (ROC) 曲线和用于生存分析的卡普兰-梅尔曲线.
主要成果:
- 与正常组织相比,质瘤组织中的HAS2-AS1表达显著增加.
- 过度表达HAS2-AS1与较差的整体存活率 (OS) 和无进展存活率 (PFS) 相相关.
- 在ROC分析中,OS (AUC=0.906) 和PFS (AUC=0.88) 的诊断值 (AUC=0.863) 和预后值都很好.
结论:
- HAS2-AS1表达有效地区分质瘤组织与正常组织.
- 升高的HAS2-AS1水平表明质瘤患者的预后不佳.
- HAS2-AS1作为质瘤的有前途的诊断和预后标志物.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
03:18Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K